VSIG4 and neoplasm: In murine experiments, targeted knockdown of VSIG4 resulted in inhibited tumour growth, accompanied by a reduction in the proportion of M2‐TAMs and exhausted T cells, alongside enhanced activity of CD8+ T cells.